Jan. 15 at 9:20 PM
$RCUS What the hell! What was the last three days about?
Arcus announcement outlining its 2026 strategic plans,
This decision, aimed at reallocating resources to higher-potential programs like its HIF-2a inhibitor casdatifan and inflammation initiatives, disappointed investors who viewed domvanalimab as a core asset. The stock fell as much as 15.4% intraday on the news, erasing recent gains and pulling back toward levels from early January. Despite this, the company emphasized optimism around casdatifan, which could become a best-in-class therapy, but the market focused on the trial halts as a setback.
Overall, the two-day run-up (Jan 13-14) was fueled by analyst optimism, pushing the stock up ~14% from Jan 12's close of
$21.30. Today's reversal wiped that out, leaving RCUS down ~5.5% net over the three-day period.
